BPG is committed to discovery and dissemination of knowledge
Cited by in F6Publishing
For: Martini PGV, Guey LT. A New Era for Rare Genetic Diseases: Messenger RNA Therapy. Hum Gene Ther 2019;30:1180-9. [PMID: 31179759 DOI: 10.1089/hum.2019.090] [Cited by in Crossref: 28] [Cited by in F6Publishing: 28] [Article Influence: 7.0] [Reference Citation Analysis]
Number Citing Articles
1 Perocheau D, Gurung S, Touramanidou L, Duff C, Sharma G, Sebire N, Finn PF, Cavedon A, Siddiqui S, Rice L, Martini PG, Frassetto A, Baruteau J. Ex vivoprimary liver sections recapitulate disease phenotype and therapeutic rescue for liver monogenic diseases.. [DOI: 10.1101/2023.03.23.533840] [Reference Citation Analysis]
2 Cao J, Markel A, Hanahoe E, Ketova T, Mihai C, Zalinger Z, Marquardt D, Amato NJ, Cheng YM, Reid DW, Dousis A, Giangrande PH, Schultz JR, Martini PGV, Finn PF. Amnio acid substitution at position 298 of human glucose-6 phosphatase-α significantly impacts its stability in mammalian cells. Amino Acids 2023. [PMID: 36944899 DOI: 10.1007/s00726-023-03263-8] [Reference Citation Analysis]
3 Capparelli R, Cuomo P, Gentile A, Iannelli D. Microbiota-Liver Diseases Interactions. Int J Mol Sci 2023;24. [PMID: 36835291 DOI: 10.3390/ijms24043883] [Reference Citation Analysis]
4 Chen MJ, Gatignol A, Scarborough RJ. The discovery and development of RNA-based therapies for treatment of HIV-1 infection. Expert Opin Drug Discov 2023;18:163-79. [PMID: 36004505 DOI: 10.1080/17460441.2022.2117296] [Reference Citation Analysis]
5 Li D, Liu Q, Yang M, Xu H, Zhu M, Zhang Y, Xu J, Tian C, Yao J, Wang L, Liang Y. Nanomaterials for mRNA ‐based Therapeutics: Challenges and Opportunities. Bioengineering & Transla Med 2023. [DOI: 10.1002/btm2.10492] [Reference Citation Analysis]
6 He Y, Li D, Wu L, Yin X, Zhang X, Patterson LH, Zhang J. Metal‐Organic Frameworks for Gene Therapy and Detection. Adv Funct Materials 2023. [DOI: 10.1002/adfm.202212277] [Reference Citation Analysis]
7 Zhao XJ, Mohsen AW, Mihalik S, Solo K, Aliu E, Shi H, Basu S, Kochersperger C, Van't Land C, Karunanidhi A, Coughlan KA, Siddiqui S, Rice LM, Hillier S, Guadagnin E, Giangrande PH, Martini PGV, Vockley J. Synthetic mRNA rescues very long-chain acyl-CoA dehydrogenase deficiency in patient fibroblasts and a murine model. Mol Genet Metab 2023;138:106982. [PMID: 36580829 DOI: 10.1016/j.ymgme.2022.106982] [Reference Citation Analysis]
8 Alvarez D, Masse-ranson G, Sedimbi SK, Wisti P, Rodriguez L, Santana J, Manning T, Towner T, Geilich B, Mihai C, Mishra A, Gurumurthy S, Frederick J, von Andrian UH, Hoggatt J, Moore MJ, Mora JR. Functional mRNA delivery to hematopoietic stem and progenitor cellsin vivo.. [DOI: 10.1101/2022.12.15.520650] [Reference Citation Analysis]
9 Jericó D, Córdoba KM, Sampedro A, Jiang L, Joucla G, Cabanne C, Lanciego JL, Martini PGV, Berraondo P, Ávila MA, Fontanellas A. Recent Insights into the Pathogenesis of Acute Porphyria Attacks and Increasing Hepatic PBGD as an Etiological Treatment. Life (Basel) 2022;12. [PMID: 36430993 DOI: 10.3390/life12111858] [Reference Citation Analysis]
10 Zhang W, Jiang Y, He Y, Boucetta H, Wu J, Chen Z, He W. Lipid carriers for mRNA delivery. Acta Pharmaceutica Sinica B 2022. [DOI: 10.1016/j.apsb.2022.11.026] [Reference Citation Analysis]
11 Okovitiy SV, Shustov EB. Exogenous RNAs as Potential Pharmacological Agents. BIOMEDICINE 2022;18:118-121. [DOI: 10.33647/2074-5982-18-3-118-121] [Reference Citation Analysis]
12 Zabaleta N, Torella L, Weber ND, Gonzalez-Aseguinolaza G. mRNA and gene editing: Late breaking therapies in liver diseases. Hepatology 2022;76:869-87. [PMID: 35243655 DOI: 10.1002/hep.32441] [Cited by in Crossref: 3] [Cited by in F6Publishing: 3] [Article Influence: 3.0] [Reference Citation Analysis]
13 Fang H, Chen Q. Applications and challenges of biomaterial mediated mRNA delivery. Exploration of Targeted Anti-tumor Therapy 2022. [DOI: 10.37349/etat.2022.00093] [Reference Citation Analysis]
14 Succoio M, Sacchettini R, Rossi A, Parenti G, Ruoppolo M. Galactosemia: Biochemistry, Molecular Genetics, Newborn Screening, and Treatment. Biomolecules 2022;12:968. [DOI: 10.3390/biom12070968] [Cited by in Crossref: 2] [Cited by in F6Publishing: 1] [Article Influence: 2.0] [Reference Citation Analysis]
15 Bangari DS, Lanigan LG, Goulet F, Siso S, Bolon B. Society of Toxicologic Pathology Neuropathology Interest Group Article: Neuropathologic Findings in Nonhuman Primates Associated With Administration of Biomolecule-Based Test Articles. Toxicol Pathol 2022;:1926233221101314. [PMID: 35695393 DOI: 10.1177/01926233221101314] [Cited by in Crossref: 1] [Cited by in F6Publishing: 1] [Article Influence: 1.0] [Reference Citation Analysis]
16 Qin S, Tang X, Chen Y, Chen K, Fan N, Xiao W, Zheng Q, Li G, Teng Y, Wu M, Song X. mRNA-based therapeutics: powerful and versatile tools to combat diseases. Signal Transduct Target Ther 2022;7:166. [PMID: 35597779 DOI: 10.1038/s41392-022-01007-w] [Cited by in Crossref: 33] [Cited by in F6Publishing: 32] [Article Influence: 33.0] [Reference Citation Analysis]
17 Seneff S, Nigh G, Kyriakopoulos AM, McCullough PA. Innate immune suppression by SARS-CoV-2 mRNA vaccinations: The role of G-quadruplexes, exosomes, and MicroRNAs. Food Chem Toxicol 2022;164:113008. [PMID: 35436552 DOI: 10.1016/j.fct.2022.113008] [Cited by in Crossref: 9] [Cited by in F6Publishing: 16] [Article Influence: 9.0] [Reference Citation Analysis]
18 Córdoba KM, Jericó D, Sampedro A, Jiang L, Iraburu MJ, Martini PG, Berraondo P, Avila MA, Fontanellas A. Messenger RNA as a personalized therapy: The moment of truth for rare metabolic diseases. mRNA-Based Therapeutics 2022. [DOI: 10.1016/bs.ircmb.2022.03.005] [Cited by in F6Publishing: 1] [Reference Citation Analysis]
19 Cohen-haguenauer O. Challenges Posed by Gene Manipulations and Sport Performance. Emerging Drugs in Sport 2022. [DOI: 10.1007/978-3-030-79293-0_4] [Reference Citation Analysis]
20 Mauro VP. Condon Optimization: Codon Optimization of Therapeutic Proteins: Suggested Criteria for Increased Efficacy and Safety. Single Nucleotide Polymorphisms 2022. [DOI: 10.1007/978-3-031-05616-1_10] [Reference Citation Analysis]
21 Gómez-aguado I, Rodríguez-castejón J, Beraza-millor M, Rodríguez-gascón A, del Pozo-rodríguez A, Solinís MÁ. mRNA delivery technologies: Toward clinical translation. mRNA-Based Therapeutics 2022. [DOI: 10.1016/bs.ircmb.2022.04.010] [Reference Citation Analysis]
22 Uchida S, Yamaberi Y, Tanaka M, Oba M. A helix foldamer oligopeptide improves intracellular stability and prolongs protein expression of the delivered mRNA. Nanoscale 2021;13:18941-6. [PMID: 34664600 DOI: 10.1039/d1nr03600a] [Cited by in Crossref: 5] [Cited by in F6Publishing: 5] [Article Influence: 2.5] [Reference Citation Analysis]
23 Heinzer D, Avar M, Pease DP, Dhingra A, Yin JA, Schaper E, Doğançay B, Emmenegger M, Spinelli A, Maggi K, Chincisan A, Mead S, Hornemann S, Heutink P, Aguzzi A. Novel regulators of PrPC biosynthesis revealed by genome-wide RNA interference. PLoS Pathog 2021;17:e1010013. [PMID: 34705895 DOI: 10.1371/journal.ppat.1010013] [Cited by in Crossref: 2] [Cited by in F6Publishing: 3] [Article Influence: 1.0] [Reference Citation Analysis]
24 Yu AM, Tu MJ. Deliver the promise: RNAs as a new class of molecular entities for therapy and vaccination. Pharmacol Ther 2021;:107967. [PMID: 34403681 DOI: 10.1016/j.pharmthera.2021.107967] [Cited by in Crossref: 9] [Cited by in F6Publishing: 10] [Article Influence: 4.5] [Reference Citation Analysis]
25 Cao J, Choi M, Guadagnin E, Soty M, Silva M, Verzieux V, Weisser E, Markel A, Zhuo J, Liang S, Yin L, Frassetto A, Graham AR, Burke K, Ketova T, Mihai C, Zalinger Z, Levy B, Besin G, Wolfrom M, Tran B, Tunkey C, Owen E, Sarkis J, Dousis A, Presnyak V, Pepin C, Zheng W, Ci L, Hard M, Miracco E, Rice L, Nguyen V, Zimmer M, Rajarajacholan U, Finn PF, Mithieux G, Rajas F, Martini PGV, Giangrande PH. mRNA therapy restores euglycemia and prevents liver tumors in murine model of glycogen storage disease. Nat Commun 2021;12:3090. [PMID: 34035281 DOI: 10.1038/s41467-021-23318-2] [Cited by in Crossref: 13] [Cited by in F6Publishing: 15] [Article Influence: 6.5] [Reference Citation Analysis]
26 Peeks F, Hoogeveen IJ, Feldbrugge RL, Burghard R, de Boer F, Fokkert-Wilts MJ, van der Klauw MM, Oosterveer MH, Derks TGJ. A retrospective in-depth analysis of continuous glucose monitoring datasets for patients with hepatic glycogen storage disease: Recommended outcome parameters for glucose management. J Inherit Metab Dis 2021;44:1136-50. [PMID: 33834518 DOI: 10.1002/jimd.12383] [Cited by in Crossref: 7] [Cited by in F6Publishing: 8] [Article Influence: 3.5] [Reference Citation Analysis]
27 Aslan C, Kiaie SH, Zolbanin NM, Lotfinejad P, Ramezani R, Kashanchi F, Jafari R. Exosomes for mRNA delivery: a novel biotherapeutic strategy with hurdles and hope. BMC Biotechnol 2021;21:20. [PMID: 33691652 DOI: 10.1186/s12896-021-00683-w] [Cited by in Crossref: 20] [Cited by in F6Publishing: 21] [Article Influence: 10.0] [Reference Citation Analysis]
28 Zhang Z, Zhang L, Wang Y, Yao J, Wang T, Weng Z, Yang L, Xie G. Ultrasensitive electrochemical biosensor for attomolar level detection of let 7a based on toehold mediated strand displacement reaction circuits and molecular beacon mediated circular strand displacement polymerization. Anal Chim Acta 2021;1147:108-15. [PMID: 33485569 DOI: 10.1016/j.aca.2020.12.057] [Cited by in Crossref: 7] [Cited by in F6Publishing: 7] [Article Influence: 3.5] [Reference Citation Analysis]
29 Delnoy B, Coelho AI, Rubio-Gozalbo ME. Current and Future Treatments for Classic Galactosemia. J Pers Med 2021;11:75. [PMID: 33525536 DOI: 10.3390/jpm11020075] [Cited by in Crossref: 8] [Cited by in F6Publishing: 8] [Article Influence: 4.0] [Reference Citation Analysis]
30 Zhao L, Wang X, Zhang X, Liu X, Ma N, Zhang Y, Zhang S. Therapeutic strategies for acute intermittent porphyria. Intractable Rare Dis Res 2020;9:205-16. [PMID: 33139979 DOI: 10.5582/irdr.2020.03089] [Cited by in Crossref: 6] [Cited by in F6Publishing: 6] [Article Influence: 2.0] [Reference Citation Analysis]
31 Yu AM, Choi YH, Tu MJ. RNA Drugs and RNA Targets for Small Molecules: Principles, Progress, and Challenges. Pharmacol Rev 2020;72:862-98. [PMID: 32929000 DOI: 10.1124/pr.120.019554] [Cited by in Crossref: 89] [Cited by in F6Publishing: 106] [Article Influence: 29.7] [Reference Citation Analysis]
32 Timson DJ. Therapies for galactosemia: a patent landscape. Pharm Pat Anal 2020;9:45-51. [PMID: 32314655 DOI: 10.4155/ppa-2020-0004] [Cited by in Crossref: 4] [Cited by in F6Publishing: 4] [Article Influence: 1.3] [Reference Citation Analysis]
33 Büning H, Bosch F, Mingozzi F. Breaking the Barriers of Genetic and Metabolic Disorders. Hum Gene Ther 2019;30:1177-9. [PMID: 31573872 DOI: 10.1089/hum.2019.29093.hbu] [Cited by in Crossref: 2] [Cited by in F6Publishing: 2] [Article Influence: 0.7] [Reference Citation Analysis]
34 Gómez-Aguado I, Rodríguez-Castejón J, Vicente-Pascual M, Rodríguez-Gascón A, Solinís MÁ, Del Pozo-Rodríguez A. Nanomedicines to Deliver mRNA: State of the Art and Future Perspectives. Nanomaterials (Basel) 2020;10:E364. [PMID: 32093140 DOI: 10.3390/nano10020364] [Cited by in Crossref: 79] [Cited by in F6Publishing: 82] [Article Influence: 26.3] [Reference Citation Analysis]
35 Abidin Z, Treacy EP. Insights into the Pathophysiology of Infertility in Females with Classical Galactosaemia. Int J Mol Sci 2019;20:E5236. [PMID: 31652573 DOI: 10.3390/ijms20205236] [Cited by in Crossref: 5] [Cited by in F6Publishing: 6] [Article Influence: 1.3] [Reference Citation Analysis]
36 Chandler RJ. Messenger RNA therapy as an option for treating metabolic disorders. Proc Natl Acad Sci U S A 2019;116:20804-6. [PMID: 31537746 DOI: 10.1073/pnas.1914673116] [Cited by in Crossref: 5] [Cited by in F6Publishing: 6] [Article Influence: 1.3] [Reference Citation Analysis]